Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer


You May Also Like

Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm

PARIS, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO) (FR0010095596), ...

Recro Pharma Reports First Quarter 2017 Financial Results

Reports First Quarter 2017 Revenues of $18.7 Million Recently Announced Successful Top-Line Results from ...